DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161966

Lipid ratios, atherogenic coefficient and atherogenic index of plasma as parameters in assessing cardiovascular risk in type 2 diabetes mellitus

Harini Devi Nimmanapalli, Ambika Devi Kasi, Prabath kumar Devapatla, Vani Nuttakki

Abstract


Background:Cardiovascular disease (CVD) is responsible for morbidity and mortality in type 2 diabetes mellitus (T2DM) patients. Diabetes alters the utilization of lipids and lipoproteins which lead to diabetes induced atherogenic dyslipidemia, one of the most important risk factor for the development of atherosclerosis. The relationship between elevation of serum lipids and vascular complications of diabetes has long been of interest. The use of LDL-c alone for assessment of cardiovascular risk would ignore the TG-rich lipoproteins. Lipid ratios, atherogenic coefficient and atherogenic index of plasma have been found to indicate an atherogenic risk and are better predictors of cardiovascular risk than lipids alone. Hence the present study is taken up to evaluate the lipid ratios, atherogenic coefficient, atherogenic index of plasma in assessing the CV risk in type 2 diabetes mellitus.

Methods: This case-control prospective study included three groups. (Group 1: control, group II: T2DM without complications, group III: T2DM with complications, n=25). Total cholesterol, triglycerides and HDL-c were analysed using commercially available kits on spectrophotometer. Nitric oxide was estimated spectrophotometrically by Griess method. VLDL, LDL, Lipid ratios, non-HDL cholesterol, AC and AIP were calculated in all the three groups. Statistical analysis was performed using SPSS version 22.0.

Results: All of the atherogenic indices were found to be significantly different upon comparing these indices in both patients and control groups.

Conclusions: The ratios contribute significantly to the estimation of CVD risk  in type 2 diabetes mellitus especially, when the absolute values of lipid profile seem normal or not markedly deranged or in centres with insufficient resources.

 


Keywords


Atherogenic dyslipidemia, Lipid ratios, Atherogenic index of plasma, Atherogenic coefficient, Cardiovascular disease

Full Text:

PDF

References


Bener A, Zirie M. Lipoprotein: a profile and HbA1c among Arabian type 2 diabetes patients. Biomedical Research. 2007;18(2):97-102.

Meng HT, Johan D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clinical Chemistry. 2004;50(7):1184-8.

Verges BL. Dyslipidaemia in diabetes mellitus, Review of the main lipoprotein abnormalities and their consequences in the development of atherogenesis. Diabetes and Metabolism. 1999;25(3):32-40.

Betteridge DJ. Diabetic dyslipidaemia. European Journal of Clinical Investigations. 1999;29(2):12-6.

Sevanian A, Asatryan I, Ziouzenkora O. Low density lipoprotein modification: basic concepts and relationship to atherosclerosis. Blood Purification. 1999;17(2,3):66-78.

Halcox JP, Schenke WH, Zalos G, Mincemoyer M, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-8.

Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27:1496-504.

Peters AL. Clinical relevance of non- HDL cholesterol in patients with diabetes. Clinical Diabetes. 2008;6(1):3-7.

Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004;50:2316-22.

Meng HT, Johan D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clinical Chemistry. 2004;50(7):1184-8.

E.George. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma christodoulakos. J Cardiovasc Pharmacol. 2006;47(4):542-8.

Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB lipoprotein depleted plasma (FER (HDL). Clinical Biochemistry. 2001;34(7):583-58.

Zak B. Cholesterol methodologies: a review. Clinical chemistry. 1977;23(7):1201-10.

Klotsch SG, McNamara JR. Triglyceride measurement. A review of methods and interference. Clinical Chemistry. 1990;36(9):1605-13.

Warwick GR, Cheung MC, Albers JJ. Comparison of current method for high density lipoprotein cholesterol quantitation. Clinical Chemistry. 1979;25(4):596-603.

Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol without use of preparative ultracentrifuge.Clinical Chemistry. 1972;18(6):499-504.

Bowers LD. Kinetic serum creatinine assays I. The role of various factors in determining specificity. Clin Chem. 1980;26(5):551-4.

Verges BL. Dyslipidaemia in diabetes mellitus, Review of the main lipoprotein abnormalities and their consequences in the development of atherogenesis. Diabetes and Metabolism. 1999;25(3):32-40.

Suchitra MM, Sheshu KM, Bitla AR, Rao AM, Alok S. Atherogenic dyslipidemia in diabetic nephropathy: lipoprotein: a lipid ratios and atherogenic index. Int J Res Med Sci. 2013;1:455-9.

Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest. 1999;29(2):12-6.

Siddiqui IA, Mariya LB , Rao JR. Lipid indices in type II diabetes mellitus and their association with macro and micro vascular complications Int J Med J Res Health Sci. 2013;2(1):87-92.

Hermans M.P, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol. 2011;28(10):20.

IndumatiV,PatilVS,KrishnaswamyD,SatishkumarD,VijayV,MaheshS,RajeshwariV,et al. Non-HDL cholesterol and LDL-c/HDL-c ratio in type II diabetic patients, International Journal of Pharma and Bio Sciences. 2011;2:71-7.

Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S, et al. Atherogenic index of plasma, castelli risk index and atherogenic coefficient- new parameters in assessing cardiovascular risk. Int J Pharm Bio Sci. 2013;3:359-64.

Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-45.

Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci. 2010;10(3):248-52.

Khazaál MS. Atherogenic Index of Plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios). Karbala J Med. 2013;6(1):1506-13.